...
首页> 外文期刊>Modern Pathology >Molecular Abnormalities of p53, MDM2, and H-ras in Synovial Sarcoma
【24h】

Molecular Abnormalities of p53, MDM2, and H-ras in Synovial Sarcoma

机译:滑膜肉瘤中p53,MDM2和H-ras的分子异常

获取原文
           

摘要

Forty-nine cases of synovial sarcoma were evaluated for mutation of the p53 gene, amplification of the MDM2 gene and mutation of the H-ras gene, and for the relation of these factors to overall survival and clinicopathologic parameters. All investigations were carried out on formalin-fixed paraffin-embedded materials. Furthermore, we evaluated the expression of p53 protein, MDM2, and p21WAF1/CIP1 immunohistochemically in these cases, together with an assessment of proliferative activities using monoclonal antibody MIB-1. Nine of the 49 cases (18.4%) had p53 gene alteration detected by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing. Eleven cases (24%) showed nuclear accumulation of p53 protein in more than 10% of the tumor cells. Among them, only three cases contained gene mutations. There was no correlation between p53 nuclear accumulation and p53 gene alteration. MDM2 gene amplification, as shown by differential PCR, was observed in 19 out of 47 cases (40%). Nineteen out of 49 cases (38.8%) showed immunoreactivity for MDM2. MDM2 gene amplification and the expression of MDM2 protein showed a significant positive relationship (P = 0.0004). Moreover, MDM2 immunoreaction was significantly correlated with nuclear accumulation of p53 protein (P = 0.023). Positive immunoreaction for p21WAF1/CIP1 was observed in 21 out of 48 cases (43.8%). p21WAF1/CIP1 expression was correlated with p53 protein expression. H-ras gene mutations were seen in only three cases (6.1%). All mutations were in codon 12 (one GGC-to-AGC [Gly-to-Ser] mutation and two GGC-to-GAC [Gly-to-Ap] mutations). The gene alteration of p53, MDM2, and H-ras did not affect the patients' prognosis. Although the cases with positive immunoreaction for p53 tended to have a worse prognosis, the difference was not statistically significant (P = 0.13). No correlation was observed between MIB-1 LI and the immunohistochemical expression of p53, MDM2, and p21WAF1/CIP1 or the mutation status of p53 and H-ras. On the other hand, high MIB-1 LI (more than 10) significantly correlated with poor prognosis (P p53 gene mutation does not appear to be a major prognostic factor and H-ras mutations are infrequent in synovial sarcoma.
机译:评估了49例滑膜肉瘤的p53基因突变,MDM2基因扩增和H-ras基因突变,以及这些因素与总体生存率和临床病理参数之间的关系。所有研究均在福尔马林固定石蜡包埋的材料上进行。此外,我们在这些情况下通过免疫组织化学方法评估了p53蛋白,MDM2和p21WAF1 / CIP1的表达,并使用单克隆抗体MIB-1评估了增殖活性。通过聚合酶链反应-单链构象多态性(PCR-SSCP)和直接测序检测到49例中的9例(18.4%)发生了p53基因改变。 11例(24%)的p53蛋白在10%以上的肿瘤细胞中呈核积累。其中只有三例含有基因突变。 p53核积累与p53基因改变之间没有相关性。如差异PCR所示,在47例病例中有19例(40%)观察到MDM2基因扩增。 49例病例中有19例(38.8%)对MDM2有免疫反应性。 MDM2基因的扩增与MDM2蛋白的表达呈显着正相关(P = 0.004)。此外,MDM2免疫反应与p53蛋白的核蓄积显着相关(P = 0.023)。 48例中有21例观察到p21WAF1 / CIP1阳性免疫反应(43.8%)。 p21WAF1 / CIP1表达与p53蛋白表达相关。仅在三例中观察到H-ras基因突变(6.1%)。所有突变均位于密码子12中(一个GGC-AGC [Gly-Ser]突变和两个GGC-GAC [Gly-Ap]突变)。 p53,MDM2和H-ras的基因改变不影响患者的预后。尽管p53免疫反应阳性的患者预后较差,但差异无统计学意义(P = 0.13)。在MIB-1 LI与p53,MDM2和p21WAF1 / CIP1的免疫组织化学表达或p53和H-ras的突变状态之间没有相关性。另一方面,高MIB-1 LI(大于10)与不良预后显着相关(P p53基因突变似乎不是主要的预后因素,滑膜肉瘤很少发生H-ras突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号